Trump, Approval
Digest more
The FDA-approved Inluriyo, an oral estrogen receptor antagonist from Eli Lilly, has shown to achieve significant improvement in progression-free survival for breast cancer.
After months of fighting, a Colorado family is breathing a sigh of relief after the FDA announced initial approval of an experimental medication helping to keep their son alive.